Premium
CD3 down‐regulating factor in sera and culture supernatants of leukaemic cells from patients with adult T cell leukaemia
Author(s) -
Matsuda Mitsuhiro,
Maeda Yasuhiro,
Shirakawa Chikashi,
Masaki Hideyuki,
Koyama Atsuko,
Horiuchi Fusanari,
Hamazaki Hiroyuki,
Fujimoto Takuya,
Irimajiri Kiyohiro,
Horiuchi Atsushi
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb08274.x
Subject(s) - peripheral blood mononuclear cell , microbiology and biotechnology , cell culture , cd3 , receptor , immunology , biology , chemistry , medicine , antigen , biochemistry , cd8 , in vitro , genetics
Immunological abnormality of T lymphocytes in patients with adult T cell leukaemia (ATL) is characterized by abnormal expression of the 55 kD chain of the receptor for interleukin 2 (IL‐2R/p55) (Tac), and the down‐regulation of CD 3 expression. Using serum and culture supernatants of leukaemic cells from ATL patients (Group A) whose CD 3 expression was down‐regulated and those (Group B) whose CD 3 was not low, the possible mechanism of CD 3 down‐regulation on ATL cells was discussed. When PBMC from normal individuals were cultured with sera from ATL patients for 24 h, CD 3 expression revealed by mean fluorescent intensity (MFI) was down‐regulated by sera from ATL patients in Group A (MFI: Pt 1 = 51.6 ± 4.5, Pt 2 = 48.0 ± 6.9, control = 96.5 ± 6.6), not by sera from patients in Group B (MFI: Pt 3 = 105.5 ± 7.9, Pt 4 = 102.5 ± 8.3, control = 96.5 ± 6.6). When normal PBMC were cultured with supernatants of leukaemic cells from ATL patients in Group A, this CD 3 down‐regulating activity was also detected (MFI: Pt 1 = 78.0 ± 10.2, Pt 2 = 70.6 ± 8.7, control = 94.0 ± 6.6). By using gel‐chromatography, the fractionated supernatants from ATL patients in Group A decreased CD 3 expression of normal PBMC significantly (MFI: Pt 1 = 22.9 ± 5.8, Pt 2 = 28.8 ± 7.4, control = 92.1 ± 9.6). This CD 3 down‐regulating activity in fractionated supernatant was not inhibited by any lymphokine antibodies, anti‐IL‐1α antibody (Ab), anti‐IL‐1B Ab, anti‐IL‐2 Ab, anti‐IL‐3 Ab, anti‐IL‐4 Ab, anti‐IL‐6 Ab, anti‐TNF‐α Ab and anti‐IFN‐γ Ab. Any known cytokines (IL‐1, IL‐2, IL‐3, IL‐4, IL‐6, TNF‐α and IFN‐γ) could not modulate CD 3 expression of normal PBMC. These findings suggested that there are novel factor(s) with CD 3 down‐regulating activity in the serum and culture supernatant of ATL patient and those factor(s) are involved in progression of ATL.